BiotechTube

T-62 Dose 1 + T-62 Dose 2

Phase 2Terminated
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postherpetic Neuralgia

Conditions

Postherpetic Neuralgia

Trial Timeline

Dec 1, 2008 → Jun 1, 2009

NCT ID
NCT00809679

About T-62 Dose 1 + T-62 Dose 2

T-62 Dose 1 + T-62 Dose 2 is a phase 2 stage product being developed by Pfizer for Postherpetic Neuralgia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00809679. Target conditions include Postherpetic Neuralgia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00809679Phase 2Terminated

Competing Products

20 competing products in Postherpetic Neuralgia

See all competitors
ProductCompanyStageHype Score
QUTENZAAstellas PharmaApproved
85
KHK6188 + PlaceboKyowa KirinPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
77
MK-8291 + PlaceboMerckPhase 1
33
Etoricoxib + PlaceboMerckApproved
85
ADL5747 + Placebo + PregabalinMerckPhase 2
52
MK0759MerckPhase 2
52
MK0686MerckPhase 2
52
Comparator: pregabalin + Comparator: Placebo (unspecified)MerckPhase 1
33
Lyrica (pregabalin) + PlaceboPfizerApproved
84
RN624 + RN624 + PlaceboPfizerPhase 2
51
T-62PfizerPhase 2
51
pregabalin + pregabalin/PF-00489791 + PlaceboPfizerPhase 2
51
PH-797804 + PlaceboPfizerPhase 2
51
Placebo + Pregabalin + Pregabalin + PregabalinPfizerPhase 3
76
pregabalinPfizerPhase 3
76
pregabalinPfizerApproved
84
HSK16149 20mg BID + HSK16149 40mg BID + Placebo BIDHaisco Pharmaceutical GroupPhase 3
74
LevetiracetamUCBPhase 2
49

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84